GLP-1 medications like Wegovy, Ozempic and Mounjaro have attracted enormous attention — and with that attention has come a wave of myths. Some people are sceptical, others have unrealistic expectations. In this article we go through seven of the most common misconceptions and set them against what the research actually shows.

Myth 1: "It's cheating — the easy way out"

One of the most common reactions is that weight loss medication is "the lazy solution." This reflects an outdated belief that obesity is purely a matter of willpower.

Research shows that obesity is a chronic disease with genetic, hormonal and neurological causes. GLP-1 receptor agonists work biologically: they mimic a natural gut hormone (GLP-1) that regulates hunger signals and blood sugar in the brain. In many people with severe obesity, the body does not produce sufficient satiety signals — the medication helps restore that balance.

Treatment still requires lifestyle changes. The major trials — including STEP 1 with semaglutide and SURMOUNT-1 with tirzepatide — combined medication with diet and exercise counselling. The medication is a tool, not a replacement for engagement.

Myth 2: "You only lose water weight"

Not true. Weight loss with GLP-1 medication is primarily fat loss. In the STEP 1 trial, participants taking 2.4 mg semaglutide weekly lost an average of 14.9% of their body weight over 68 weeks — compared with 2.4% in the placebo group. Body composition studies show that most of the loss comes from fat tissue, not water or muscle (provided adequate protein intake and exercise).

Myth 3: "This medication is only for people with diabetes"

Ozempic (semaglutide 1 mg) is approved for type 2 diabetes, but Wegovy (semaglutide 2.4 mg) is specifically approved for the treatment of obesity in adults without diabetes — by the EMA in Europe and the FDA in the USA. Mounjaro/Zepbound (tirzepatide) is approved for both indications.

The typical eligibility criteria for Wegovy are a BMI ≥ 30, or ≥ 27 with at least one weight-related condition such as high blood pressure or sleep apnoea. Diabetes is not a requirement.

Myth 4: "GLP-1 medication is dangerous — it's experimental"

Semaglutide has been in clinical use since 2017 (as Ozempic) and is now one of the most extensively studied drugs in recent history. Wegovy has been FDA-approved since 2021 and EMA-approved since 2022. It is not experimental.

Like all medications it has side effects — most commonly nausea, vomiting and diarrhoea, especially when starting treatment. These are typically mild to moderate and ease over time. Serious side effects (pancreatitis, gallbladder problems) can occur but are rare. Your doctor assesses the risks and benefits for your individual situation.

Myth 5: "You become addicted to the medication"

GLP-1 medications do not create chemical dependency. There is no euphoric effect, no classical withdrawal. What many people notice when stopping is that hunger and cravings return — that is biology, not addiction.

Obesity, like many chronic diseases, often requires ongoing treatment. Just as we would not say that a person with high blood pressure is "addicted" to their blood pressure medication, it is not appropriate to use that word for GLP-1 treatment.

Myth 6: "The weight always comes back — it's pointless"

This is partly true, but context matters. Studies show that many people regain a significant portion of their lost weight within one to two years of stopping the medication. But this happens because the body has a biological "set-point" mechanism that tries to return to baseline — not because the medication failed.

For many patients the solution is long-term treatment, just as high blood pressure or high cholesterol is managed continuously. Furthermore, even a temporary weight loss of 10–15% is associated with meaningful health benefits: lower blood pressure, better blood sugar control and reduced risk of cardiovascular disease.

Myth 7: "You don't need to change your diet while on the medication"

The medication significantly reduces hunger, but it does not remove the need for a healthy diet. If you mainly eat ultra-processed foods with low nutritional value, you risk deficiencies in protein, vitamins and minerals — especially because you are eating far less than before.

All major clinical trials included dietary counselling as part of the protocol. It is recommended to prioritise protein-rich foods (chicken, eggs, legumes, fish), vegetables and wholegrains, and to limit sugar and processed food. It is not impossible to lose weight without changing habits, but results are far better with a healthy eating plan.

What does the research say?

The most striking results come from:

The medication works — but it is not a miracle. It works best as part of a comprehensive approach to weight management.

When should you talk to your doctor?

If you are considering GLP-1 treatment, always consult a doctor first. They can assess whether the medication is right for you, review your risk factors and help set realistic goals. Do not use these medications without a prescription or based solely on online information.

Sources